Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Maurizio Pompili, Claudio Verzura, Giada Trovini, Andrea Buscajoni, Giulia Falcone, Stefano Naim, Adele Nardella, Serena Sorice, Ross J Baldessarini & Paolo Girardi. (2018) Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders. Expert Opinion on Drug Safety 17:2, pages 197-205.
Read now
Read now
Guido Di Sciascio & Marco Andrea Riva. (2015) Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatric Disease and Treatment 11, pages 2635-2647.
Read now
Read now
Mauro Giovanni Carta, Maria Francesca Moro, Antonio E Nardi & Joseph R Calabrese. (2015) Potential use of lurasidone for the treatment of bipolar psychosis. Expert Opinion on Investigational Drugs 24:4, pages 575-584.
Read now
Read now
Ricardo P Garay, Ludovic Samalin, Ahcène Hameg & Pierre-Michel Llorca. (2015) Investigational drugs for anxiety in patients with schizophrenia. Expert Opinion on Investigational Drugs 24:4, pages 507-517.
Read now
Read now
Articles from other publishers (18)
Veronica Begni, Moira Marizzoni, Kerstin Camile Creutzberg, Diana Morena Silipo, Mariusz Papp, Annamaria Cattaneo & Marco Andrea Riva. (2024) Transcriptomic analyses of rats exposed to chronic mild stress: Modulation by chronic treatment with the antipsychotic drug lurasidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 129, pages 110885.
Crossref
Crossref
Orwa Siddig, Chenxi Liu, Mohamed Abdulbagi, Min Song, Yu-ting Lu & Tai-jun Hang. (2024) Separation and characterization of related substances of Lurasidone hydrochloride by LC-QTOF-MS techniques. Journal of Pharmaceutical and Biomedical Analysis 238, pages 115834.
Crossref
Crossref
Kerstin Camile Creutzberg, Veronica Begni, Francesca Marchisella, Mariusz Papp & Marco Andrea Riva. (2023) Early effects of lurasidone treatment in a chronic mild stress model in male rats. Psychopharmacology 240:4, pages 1001-1010.
Crossref
Crossref
V. Begni, I. Pisano, M. Marizzoni, F. Marchisella, K.C. Creutzberg, F. De Rosa, A. Cattaneo, P. Gruca, E. Litwa, M. Papp & M.A. Riva. (2022) Exposure to chronic stress impairs the ability to cope with an acute challenge: Modulation by lurasidone treatment. European Neuropsychopharmacology 61, pages 78-90.
Crossref
Crossref
Marco Andrea Riva, Umberto Albert, Sergio de Filippis, Antonio Vita & Domenico De Berardis. (2021) Identification of clinical phenotypes in schizophrenia: the role of lurasidone. Therapeutic Advances in Psychopharmacology 11, pages 204512532110122.
Crossref
Crossref
Annamaria Cattaneo, Matthew Suderman, Nadia Cattane, Monica Mazzelli, Veronica Begni, Carlo Maj, Ilari D'Aprile, Carmine M. Pariante, Alessia Luoni, Alessandra Berry, Katharina Wurst, Leif Hommers, Katharina Domschke, Francesca Cirulli, Moshe Szyf, Andreas Menke & Marco A. Riva. (2020) Long-term effects of stress early in life on microRNA-30a and its network: Preventive effects of lurasidone and potential implications for depression vulnerability. Neurobiology of Stress 13, pages 100271.
Crossref
Crossref
Herbert Y. Meltzer, Daniel B. Share, Karu Jayathilake, Ronald M. Salomon & Myung A. Lee. (2020) Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology 40:3, pages 240-249.
Crossref
Crossref
Andrea C Rossetti, Maria Serena Paladini, Martina Colombo, Piotr Gruca, Magdalena Lason-Tyburkiewicz, Katarzyna Tota-Glowczyk, Mariusz Papp, Marco A Riva & Raffaella Molteni. (2018) Chronic Stress Exposure Reduces Parvalbumin Expression in the Rat Hippocampus through an Imbalance of Redox Mechanisms: Restorative Effect of the Antipsychotic Lurasidone. International Journal of Neuropsychopharmacology 21:9, pages 883-893.
Crossref
Crossref
Jill M. PulleyRebecca N. JeromeNicole M. ZaleskiJana K. Shirey-RiceAndrea J. PruijssersRobert R. LavieriSomsundaram N. ChettiarHelen M. NaylorDavid M. AronoffDavid A. EdwardsColleen M. NiswenderLaura L. DuganLeslie J. CroffordGordon R. BernardKenneth J. Holroyd. (2017) When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. ASSAY and Drug Development Technologies 15:8, pages 354-361.
Crossref
Crossref
Lakshmi Rajagopal, Sunoh Kwon, Mei Huang, Eric Michael, Laxminarayan Bhat, Marc Cantillon & Herbert Y. Meltzer. (2017) RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behavioural Brain Research 332, pages 180-199.
Crossref
Crossref
A. Luoni, J. Richetto, L. Longo & M.A. Riva. (2017) Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation. European Neuropsychopharmacology 27:2, pages 170-179.
Crossref
Crossref
Francesca Calabrese, Elisa Savino, Mariusz Papp, Raffaella Molteni & Marco A. Riva. (2016) Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment. Pharmacological Research 104, pages 140-150.
Crossref
Crossref
Andrea C. Rossetti, Mariusz Papp, Piotr Gruca, Maria Serena Paladini, Giorgio Racagni, Marco A. Riva & Raffaella Molteni. (2016) Stress-induced anhedonia is associated with the activation of the inflammatory system in the rat brain: Restorative effect of pharmacological intervention. Pharmacological Research 103, pages 1-12.
Crossref
Crossref
L. Samalin, M. Honciuc & P.-M. Llorca. (2015) Efficacité et tolérance à long terme de la lurasidone dans la prise en charge de la schizophrénie. L'Encéphale 41:6, pages 541-549.
Crossref
Crossref
Mark J. Millan, Guy M. Goodwin, Andreas Meyer-Lindenberg & Sven Ove Ögren. (2015) Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology 25:5, pages 599-656.
Crossref
Crossref
Konstantinos N. Fountoulakis, Maria Gazouli, John Kelsoe & Hagop Akiskal. (2015) The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder. European Neuropsychopharmacology 25:3, pages 335-342.
Crossref
Crossref
Alessia Luoni, Flavia Macchi, Mariusz Papp, Raffaella Molteni & Marco A. Riva. (2015) Lurasidone Exerts Antidepressant Properties in the Chronic Mild Stress Model through the Regulation of Synaptic and Neuroplastic Mechanisms in the Rat Prefrontal Cortex. International Journal of Neuropsychopharmacology 18:4.
Crossref
Crossref
B. Levant. 2014. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.